Bexagliflozin Efficacy and Safety Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1700 participants.

Also called NCT02558296

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,700 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02558296
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Mexico, Netherlands, Poland, Russia, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02558296. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (actual); primary completion 2018-08 (actual). Results posted on 2021-07-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bexagliflozin Efficacy and Safety Trial
Acronym
BEST
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct02558296
Content hash
f47d796ff2c6144a1ceaf28484e95dcac2a1dae69ff9aad9989fc6d6feb67129